Autoimmune Disease Treatment
Pharmacological strategies for autoimmune diseases -- from conventional DMARDs to biologics and targeted synthetic agents across major disease categories.
## Treatment Paradigm
Autoimmune disease treatment follows a hierarchical approach: induce remission, maintain remission, and minimize long-term drug toxicity. The treat-to-target strategy adjusts therapy based on disease activity measures, aiming for remission or low disease activity rather than symptom control alone.
The therapeutic arsenal includes conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs, primarily JAK inhibitors).
## Conventional DMARDs
**Methotrexate** is the anchor drug for rheumatoid arthritis and many other autoimmune conditions. At low doses (7.5-25 mg/week), it acts as an immunomodulator via adenosine release and folate pathway inhibition, suppressing lymphocyte proliferation and inflammatory cytokine production. Folic acid supplementation (1-5 mg/day) reduces mucosal and hepatic toxicity. Monitoring includes regular CBC and liver function tests.
**Hydroxychloroquine** modulates lysosomal pH, inhibiting antigen processing and TLR signaling. It is a cornerstone of SLE treatment (reduces flares, thrombosis, and mortality) and is used in rheumatoid arthritis. Retinal toxicity risk increases after 5 years, mandating annual ophthalmologic screening.
**Sulfasalazine**, **leflunomide** (pyrimidine synthesis inhibitor), and **cyclophosphamide** (alkylating agent, reserved for severe organ-threatening disease) complete the conventional DMARD armamentarium.
## Biologic DMARDs
When csDMARDs provide insufficient control, biologics target specific immune pathways:
- **Anti-TNF** (adalimumab, etanercept, infliximab): First-line biologics for RA, typically combined with methotrexate
- **Anti-IL-6R** (tocilizumab, sarilumab): Effective as monotherapy when methotrexate is contraindicated
- **CTLA-4-Ig** (abatacept): Blocks T-cell co-stimulation
- **Anti-CD20** (rituximab): B-cell depletion for refractory RA, ANCA vasculitis, and pemphigus
Disease-specific biologics include belimumab (SLE), secukinumab (psoriasis, ankylosing spondylitis), and vedolizumab (gut-selective integrin blocker for IBD).
## JAK Inhibitors
**Tofacitinib** (JAK1/3), **baricitinib** (JAK1/2), and **upadacitinib** (JAK1-selective) are oral small molecules that block intracellular cytokine signaling. Advantages include oral administration, rapid onset, and broad efficacy across multiple autoimmune conditions. However, post-marketing data (ORAL Surveillance trial) raised concerns about cardiovascular events, malignancy, and thrombosis in older patients with cardiovascular risk factors, leading to FDA boxed warnings and positioning after biologic DMARD failure in some guidelines.
## Disease-Specific Approaches
**SLE**: Hydroxychloroquine (universal), mycophenolate or cyclophosphamide for nephritis, belimumab for refractory disease, voclosporin for lupus nephritis.
**Inflammatory bowel disease**: Step-up from mesalamine (UC) to thiopurines, then biologics (anti-TNF, vedolizumab, ustekinumab) or JAK inhibitors (tofacitinib for UC).
**Multiple sclerosis**: Distinct pharmacology with disease-modifying therapies ranging from interferons to natalizumab, ocrelizumab, and sphingosine-1-phosphate modulators.
## Key Takeaways
- Methotrexate remains the first-line DMARD for rheumatoid arthritis and many autoimmune diseases
- Biologics target specific cytokines or cell populations when csDMARDs are insufficient
- JAK inhibitors offer oral convenience but carry boxed warnings for cardiovascular and malignancy risks
- Treat-to-target strategies optimize outcomes by adjusting therapy to disease activity measures